<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630747</url>
  </required_header>
  <id_info>
    <org_study_id>TKT024EXT</org_study_id>
    <secondary_id>2004-002743-27</secondary_id>
    <nct_id>NCT00630747</nct_id>
  </id_info>
  <brief_title>Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Idursulfase</brief_title>
  <official_title>An Open-Label Extension of Study TKT024 Evaluating Long-Term Safety and Clinical Outcomes in MPS II Patients Receiving Iduronate-2-Sulfatase Enzyme Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study TKT024EXT was a long-term, single-arm, open-label extension of Study TKT024, a one year
      Phase 2/Phase 3 registration study. The primary objective of this extension study was to
      collect long-term safety and clinical outcome data in Mucopolysaccharidosis II (MPS II), also
      known as Hunter Syndrome, from the Phase 2/Phase 3 Study TKT024. All patients enrolling into
      this study received weekly active treatment with idursulfase, the primary dosing regimen
      investigated in Study TKT024.

      Hunter Syndrome is an X-linked recessive lysosomal storage disease caused by a deficiency of
      iduronate-2-sulfatase, an enzyme required to catabolize glycosaminoglycans (GAGS) in cells.
      As a result, GAGs accumulate in the lysosomes leading to cellular engorgement, organomegaly,
      tissue destruction, and organ system dysfunction. Hunter Syndrome is a rare disease with an
      estimated incidence of 1 in 162,000 live births.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study TKT024EXT was conducted in 2 phases. The first phase (&quot;Phase I&quot;) was 2 years (104
      weeks) in duration and consisted of weekly infusions of IV idursulfase (0.5 mg/kg), and the
      collection of patients' safety and clinical outcomes. Week 105 defined the beginning of the
      second phase of the study. The second phase (&quot;Phase II&quot;) consisted of weekly infusions of IV
      idursulfase (0.5 mg/kg) and the monitoring of patients for safety (via collection of adverse
      events, concomitant medications, and vital signs). Study completion was defined as the time a
      patient either transitioned to commercially available idursulfase or discontinued this study.

      Idursulfase was administered to patients as a continuous IV infusion at a dose of 0.5 mg of
      protein per kg of body weight (0.5 mg/kg). Final evaluations from Study TKT024, the one-year
      predecessor Phase 2/Phase 3 registration study, served as the baseline assessments for the
      TKT024EXT study. Forced vital capacity (FVC) and the 6-minute walk test (6MWT) continued to
      be the primary clinical outcomes of TKT024EXT study. Efficacy outcomes were evaluated over
      the course of 2 years and were determined at 4-month intervals during the first year (ie,
      Weeks 18, 36, and 53) and at 6-month intervals in the second year (ie, Weeks 79 and 105).
      Safety outcomes were assessed throughout the duration of the study. The safety and clinical
      testing performed in the TKT024EXT study were identical to those performed in the
      double-blind phase of Study TKT024.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105</measure>
    <time_frame>Baseline and at Week 105</time_frame>
    <description>Determined by spirometry. The change is calculated as Week 105 minus baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Distance Walked in the 6-minute Walk Test (6MWT) at Week 105</measure>
    <time_frame>Baseline and at Week 105</time_frame>
    <description>Determined on a walking course. The change was calculated as Week 105 minus baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Passive Joint Range of Motion (JROM) at Week 105</measure>
    <time_frame>Baseline and at Week 105</time_frame>
    <description>Change was calculated as Week 105 minus baseline. Global JROM (% normal range of motion) is the average of 11 ratios multiplied by 100. Ratios are Left/Right means of passive range of motion in Shoulder (Flexion/Extension, Abduction, Internal/External Rotation), Elbow (Flexion/Extension), Wrist (Flexion/Extension), Index Finger (Flexion/Extension [Combined Metacarpophalangeal joint (MCP), Proximal interphalangeal joint (PIP), Distal interphalangeal joint (DIP) motion]), Hip (Flexion/Extension, Abduction, Internal/External Rotation), Knee (Flexion/Extension), and Ankle (Dorsiflexion) divided by the normal range (American Academy of Orthopedic Surgeons and American Medical Association).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Combined Liver and Spleen Volume at Week 105</measure>
    <time_frame>Baseline and at Week 105</time_frame>
    <description>Determined by Magnetic Resonance Imaging (MRI). The change was calculated as Week 105 minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Normalized Urine Glycosaminoglycans (GAG) Levels at Week 105</measure>
    <time_frame>Baseline and at Week 105</time_frame>
    <description>Determined by urine testing. The change was calculated as Week 105 minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Mean Cardiac Left Ventricular Mass Index (LVMI) at Week 105</measure>
    <time_frame>Baseline and at Week 105</time_frame>
    <description>Determined by echocardiogram. LVMI indexed to body surface area (g/m^2). The change was calculated as Week 105 minus baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Hunter Syndrome</condition>
  <condition>Mucopolysaccharidosis II (MPS II)</condition>
  <arm_group>
    <arm_group_label>Idursulfase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Idursulfase</intervention_name>
    <description>Solution for intravenous infusion, 0.5 mg/kg once-weekly</description>
    <arm_group_label>Idursulfase</arm_group_label>
    <other_name>ElapraseÂ®</other_name>
    <other_name>iduronate-2-sulfatase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must have completed the double-blind phase of Study TKT024, defined as
             completing the Week 53 final evaluations.

          -  Patient, patient's parent(s), or legally authorized representative must have
             voluntarily signed an Institutional Review Board (IRB)/Independent Ethics Committee
             (IEC)-approved informed consent form after all relevant aspects of the study have been
             explained and discussed with the patient.

        Exclusion Criteria:

          -  Patient has received treatment with an investigational therapy other than
             iduronate-2-sulfatase in Study TKT024 within the past 60 days.

          -  Patient is unable to comply with the protocol (e.g., due to a medical condition such
             as cervical cord compression or uncooperative attitude) or is unlikely to complete the
             study, as determined by the investigator.

          -  Patient has experienced an adverse reaction to study drug in Study TKT024, which
             contraindicates further treatment with idursulfase.

          -  Patient with known hypersensitivity to any of the components of idursulfase.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Muenzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kirk Aleck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Giugliani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Beck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's University Hospital Mainz AG</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Uma Ramaswami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge University Hospitals NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ashok Vellodi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Great Ormond Street Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. Edmond Wraith, MRCP, FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Manchester Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Harmatz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pediatric Clinical Research Center, Children's Hospital Oakland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rick Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Louis University Cardinal Glennon Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christine Eng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine Texas Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Maria Martins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIFESP Instituto de Oncologia Pediatrica</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Angelina Acosta, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>c-HUPES/UFBA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto da Crianca / Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Durval Batista Palhares, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emerson Santos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcia Ribeiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto de Puericultura e Pediatria Martagao Gesteira / Hospital Pediatrico</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roberto Garcia De Lima, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Casa de Saude Sao Joao</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Emmanuelle Lemyre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Montreal / Hopital Ste-Justine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joe Clarke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Hospital for Sick Children Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie Guffon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Edouard Herriot</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel Fischbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HÃ´pital de Hautepierre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francis Gaches, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Ducuing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf Mertens, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum Aachen Kinderklinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bjorn Hoffmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinik Dusseldorf Kinderklinik</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Steinfeld, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum Gottingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joachim Kreuder, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Justus-Liebig Universitat</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kurt Ullrich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitatsklinikum Hamburg Eppendorf</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luigi Besenzon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale S. S. Annunziata</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maurizio Scarpa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita di Padova</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rossella Parini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita Milano Bicocca / Ospedale S. Gerardo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Generoso Andria, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universita degli Studi di Napoli Federico II</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paula Grigorescu Sido, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Spitalul Clinic de Copii</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Guillem Pintos-Morell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Germans Trias i Pujol</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonia Patrocinio Leon Asensio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Pediatria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pilar Munguira Aguado, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Servicio de Pediatria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Uvebrant, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Drottning Silvias Barnsjukhus</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunilla Malm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mal Ratnayaka, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Derbyshire Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter H. Robinson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Hospital for Sick Children</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Ryalls, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Surrey County Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicola Leech, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Infirmary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stuart Murray, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bath and NE Somerset Primary Care Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janet Thomas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Children's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sara Copeland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Iowa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hwan Jeong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid-Illinois Hematology and Oncology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Kline, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Cancer Centers of Nevada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Neilan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Childrenâs Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>G. Bradley Schaefer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paige Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dilip Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbin Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dave Viskochil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Cherrick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upstate Medical University, State University of New York (SUNY)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Capelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Franciscan Skemp Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pediatric Clinical Research Center, Children's Hospital Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbin Clinic</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid-Illinois Hematology and Oncology Associates</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>61761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospitals and Clinics</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Cardinal Glennon Children's Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Medical University, State University of New York (SUNY)</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscan Skemp Healthcare</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Universidade de Ciencias da Saude de Alagoas Governador Lamenha Filho / UNCISAL</name>
      <address>
        <city>Maceio</city>
        <state>AL</state>
        <zip>57010-382</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Casa de Saude Sao Joao</name>
      <address>
        <city>Barreiras</city>
        <state>BA</state>
        <zip>47800-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>c-HUPES/UFBA</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario da Faculdade de Medicina da Universidade Federal de Mato Grosso do Sul</name>
      <address>
        <city>Campo Grande</city>
        <state>MS</state>
        <zip>79008-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Puericultura e Pediatria Martagao Gesteira / Hospital Pediatrico</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21941-590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNIFESP Instituto de Oncologia Pediatrica</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto da Crianca / Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1XB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Montreal / Hopital Ste-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Hautepierre</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ducuing</name>
      <address>
        <city>Toulouse Cedex</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Aachen Kinderklinik</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Dusseldorf Kinderklinik</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig Universitat</name>
      <address>
        <city>Giessen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Gottingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's University Hospital Mainz AG</name>
      <address>
        <city>Mainz</city>
        <zip>55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Milano Bicocca / Ospedale S. Gerardo</name>
      <address>
        <city>Monza (Milano)</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale S. S. Annunziata</name>
      <address>
        <city>Savigliano (Cuneo)</city>
        <zip>12038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalul Clinic de Copii</name>
      <address>
        <city>Cluj Napoca</city>
        <state>Cluj</state>
        <zip>400370</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Pediatria</name>
      <address>
        <city>Linares (Jaen)</city>
        <zip>23700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drottning Silvias Barnsjukhus</name>
      <address>
        <city>Gothenberg</city>
        <zip>41685</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bath and NE Somerset Primary Care Trust</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3QE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Derbyshire Children's Hospital</name>
      <address>
        <city>Derby</city>
        <zip>DE22 3NE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Hospital for Sick Children</name>
      <address>
        <city>Glasgow</city>
        <zip>G3 8SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital for Sick Children</name>
      <address>
        <city>London</city>
        <zip>WC1N3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M27 4HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Infirmary</name>
      <address>
        <city>Newcastle</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Surrey County Hospital</name>
      <address>
        <city>Surrey</city>
        <zip>GU2 5XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Romania</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab. 2007 Mar;90(3):329-37. Epub 2006 Dec 20.</citation>
    <PMID>17185020</PMID>
  </reference>
  <reference>
    <citation>Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, Vijayaraghavan S, Wendt S, Puga AC, Ulbrich B, Shinawi M, Cleary M, Piper D, Conway AM, Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006 Aug;8(8):465-73. Erratum in: Genet Med. 2006 Sep;8(9):599. Wendt, Suzanne [corrected to Wendt, Susanne]; Puga, Antonio [corrected to Puga, Ana Cristina]; Conway, Ann Marie [corrected to Conway, Anne Marie].</citation>
    <PMID>16912578</PMID>
  </reference>
  <results_reference>
    <citation>Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, Ramaswami U, Vellodi A, Wraith JE, Cleary M, Gucsavas-Calikoglu M, Puga AC, Shinawi M, Ulbrich B, Vijayaraghavan S, Wendt S, Conway AM, Rossi A, Whiteman DA, Kimura A. Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med. 2011 Feb;13(2):95-101. doi: 10.1097/GIM.0b013e3181fea459. Erratum in: Genet Med. 2013 Oct;15(10):849.</citation>
    <PMID>21150784</PMID>
  </results_reference>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>February 27, 2012</results_first_submitted>
  <results_first_submitted_qc>January 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 17, 2014</results_first_posted>
  <last_update_submitted>July 16, 2015</last_update_submitted>
  <last_update_submitted_qc>July 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hunter syndrome</keyword>
  <keyword>hunters syndrome</keyword>
  <keyword>hunter's syndrome</keyword>
  <keyword>hunter disease</keyword>
  <keyword>hunters disease</keyword>
  <keyword>hunter's disease</keyword>
  <keyword>MPS II</keyword>
  <keyword>MPSII</keyword>
  <keyword>MPS2</keyword>
  <keyword>MPS 2</keyword>
  <keyword>mucopolysaccharides</keyword>
  <keyword>lysosomal storage disease</keyword>
  <keyword>lysosomal storage disorder</keyword>
  <keyword>chronic ear infection</keyword>
  <keyword>enlarged adenoids</keyword>
  <keyword>mps symptoms</keyword>
  <keyword>mps diagnosis</keyword>
  <keyword>mps ii therapy</keyword>
  <keyword>MPS II treatment</keyword>
  <keyword>ert treatment</keyword>
  <keyword>elaprase</keyword>
  <keyword>idursulfase</keyword>
  <keyword>iduronate sulfatase</keyword>
  <keyword>iduronate 2 sulfatase</keyword>
  <keyword>enzyme replacement therapy</keyword>
  <keyword>hunter syndrome treatment</keyword>
  <keyword>hunter's syndrome treatment</keyword>
  <keyword>hunter syndrome therapy</keyword>
  <keyword>hunter's disease treatment</keyword>
  <keyword>mps society</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study allows participants in double-blind phase of Study TKT024 (NCT00069641), a 1 year Phase 2/3 registration study, to continue long-term idursulfase therapy and to allow placebo participants in TKT024 to receive active idursulfase treatment. The first participant enrolled on 13 Sep 2004. The study was conducted at 52 sites in 17 countries.</recruitment_details>
      <pre_assignment_details>Participants were screened for entry based on their known medical histories and previous participation in the TKT024 study. Participants had to have completed Week 53 final evaluations in the TKT024 study. Participants were not to have received any treatment with an investigational therapy other than idursulfase within 60 days of study entry.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
          <description>Idursulfase 0.5 milligram per kilogram (mg/kg) administered by intravenous (IV) infusion once-weekly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Treated in Phase I of Study</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to Study TKT031NPU</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Returned to country of origin</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
          <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.52" spread="6.634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Percent Predicted Forced Vital Capacity (FVC)</title>
          <units>percent predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.160" spread="14.897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Distance Walked in the 6-minute Walk Test (6MWT)</title>
          <units>meters (m)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="400.3" spread="100.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Passive Joint Range of Motion (JROM)</title>
          <description>Global JROM (% normal range of motion) is the average of 11 ratios multiplied by 100. Ratios are Left/Right means of passive range of motion in Shoulder (Flexion/Extension, Abduction, Internal/External Rotation), Elbow (Flexion/Extension), Wrist (Flexion/Extension), Index Finger (Flexion/Extension [Combined MCP, PIP, DIP motion]), Hip (Flexion/Extension, Abduction, Internal/External Rotation), Knee (Flexion/Extension), and Ankle (Dorsiflexion) divided by the normal range (American Academy of Orthopedic Surgeons and American Medical Association).</description>
          <units>percentage of JROM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.44" spread="9.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Combined Liver and Spleen Volume</title>
          <units>cubic centimeters (cc)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1504.8" spread="417.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Normalized Urine Glycosaminoglycans (GAG) Levels</title>
          <units>microgram(mcg)GAG/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="361.96" spread="136.132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline Cardiac Left Ventricular Mass Index (LVMI)</title>
          <units>gram per meter^2 (g/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.64" spread="36.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105</title>
        <description>Determined by spirometry. The change is calculated as Week 105 minus baseline.</description>
        <time_frame>Baseline and at Week 105</time_frame>
        <population>All participants for whom percent predicted FVC were recorded at baseline and at Week 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
            <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105</title>
          <description>Determined by spirometry. The change is calculated as Week 105 minus baseline.</description>
          <population>All participants for whom percent predicted FVC were recorded at baseline and at Week 105.</population>
          <units>percent predicted FVC</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.056" spread="1.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Passive Joint Range of Motion (JROM) at Week 105</title>
        <description>Change was calculated as Week 105 minus baseline. Global JROM (% normal range of motion) is the average of 11 ratios multiplied by 100. Ratios are Left/Right means of passive range of motion in Shoulder (Flexion/Extension, Abduction, Internal/External Rotation), Elbow (Flexion/Extension), Wrist (Flexion/Extension), Index Finger (Flexion/Extension [Combined Metacarpophalangeal joint (MCP), Proximal interphalangeal joint (PIP), Distal interphalangeal joint (DIP) motion]), Hip (Flexion/Extension, Abduction, Internal/External Rotation), Knee (Flexion/Extension), and Ankle (Dorsiflexion) divided by the normal range (American Academy of Orthopedic Surgeons and American Medical Association).</description>
        <time_frame>Baseline and at Week 105</time_frame>
        <population>All participants for whom passive JROM were recorded at baseline and at Week 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
            <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Passive Joint Range of Motion (JROM) at Week 105</title>
          <description>Change was calculated as Week 105 minus baseline. Global JROM (% normal range of motion) is the average of 11 ratios multiplied by 100. Ratios are Left/Right means of passive range of motion in Shoulder (Flexion/Extension, Abduction, Internal/External Rotation), Elbow (Flexion/Extension), Wrist (Flexion/Extension), Index Finger (Flexion/Extension [Combined Metacarpophalangeal joint (MCP), Proximal interphalangeal joint (PIP), Distal interphalangeal joint (DIP) motion]), Hip (Flexion/Extension, Abduction, Internal/External Rotation), Knee (Flexion/Extension), and Ankle (Dorsiflexion) divided by the normal range (American Academy of Orthopedic Surgeons and American Medical Association).</description>
          <population>All participants for whom passive JROM were recorded at baseline and at Week 105.</population>
          <units>percentage of JROM</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.63" spread="0.640"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Combined Liver and Spleen Volume at Week 105</title>
        <description>Determined by Magnetic Resonance Imaging (MRI). The change was calculated as Week 105 minus baseline.</description>
        <time_frame>Baseline and at Week 105</time_frame>
        <population>All participants for whom combined liver and spleen volume were recorded at baseline and at Week 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
            <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Combined Liver and Spleen Volume at Week 105</title>
          <description>Determined by Magnetic Resonance Imaging (MRI). The change was calculated as Week 105 minus baseline.</description>
          <population>All participants for whom combined liver and spleen volume were recorded at baseline and at Week 105.</population>
          <units>cubic centimeters (cc)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-325.5" spread="36.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Normalized Urine Glycosaminoglycans (GAG) Levels at Week 105</title>
        <description>Determined by urine testing. The change was calculated as Week 105 minus baseline.</description>
        <time_frame>Baseline and at Week 105</time_frame>
        <population>All participants for whom normalized urine GAG levels were recorded at baseline and at Week 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
            <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Normalized Urine Glycosaminoglycans (GAG) Levels at Week 105</title>
          <description>Determined by urine testing. The change was calculated as Week 105 minus baseline.</description>
          <population>All participants for whom normalized urine GAG levels were recorded at baseline and at Week 105.</population>
          <units>mcg GAG/mg creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-238.25" spread="13.333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Mean Cardiac Left Ventricular Mass Index (LVMI) at Week 105</title>
        <description>Determined by echocardiogram. LVMI indexed to body surface area (g/m^2). The change was calculated as Week 105 minus baseline.</description>
        <time_frame>Baseline and at Week 105</time_frame>
        <population>All participants for whom cardiac LVM were recorded at baseline and at Week 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
            <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Cardiac Left Ventricular Mass Index (LVMI) at Week 105</title>
          <description>Determined by echocardiogram. LVMI indexed to body surface area (g/m^2). The change was calculated as Week 105 minus baseline.</description>
          <population>All participants for whom cardiac LVM were recorded at baseline and at Week 105.</population>
          <units>g/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="3.826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Distance Walked in the 6-minute Walk Test (6MWT) at Week 105</title>
        <description>Determined on a walking course. The change was calculated as Week 105 minus baseline.</description>
        <time_frame>Baseline and at Week 105</time_frame>
        <population>All participants for whom distance walked was recorded at baseline and at Week 105.</population>
        <group_list>
          <group group_id="O1">
            <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
            <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Distance Walked in the 6-minute Walk Test (6MWT) at Week 105</title>
          <description>Determined on a walking course. The change was calculated as Week 105 minus baseline.</description>
          <population>All participants for whom distance walked was recorded at baseline and at Week 105.</population>
          <units>meters (m)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" spread="7.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed throughout the duration of the TKT024EXT study. Adverse events were monitored from the time the first participant signed the informed consent until approximately 30 days after the last study visit.</time_frame>
      <desc>The &quot;Serious Adverse Events&quot; table lists all serious adverse events that occurred during the study regardless of a relationship to the study drug. The &quot;Other Adverse Events&quot; table lists those non-serious adverse events that were were determined to be possibly related to the study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Idursulfase (0.5 mg/kg, IV, Once-weekly)</title>
          <description>Idursulfase 0.5 mg/kg administered by IV infusion once-weekly.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia (Not Otherwise Specified [NOS])</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pericardial Effusions</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tympanic Membrane Disorder NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Abdominal Pain NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Abdominal Strangulated Hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Diarrhea NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Related Complications</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hernia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <description>2 events of bacteraemia were at least possibly related to study drug as determined by the investigator.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Endocarditis Bacterial NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis Media Chronic NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis Media NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis Media Serous Chronic NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis Media Serous NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <description>1 event of pneumonia NOS was at least possibly related to study drug as determined by the investigator.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Airway Complication of Anaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired Claw Toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Joint Contracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain in Foot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neurilemmoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression NOS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychosomatic Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma Aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Foreign Body Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder NOS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tracheal Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Macular</sub_title>
                <description>This event of rash macular was at least possibly related to study drug as determined by the investigator.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Poor Venous Access</sub_title>
                <description>1 event of poor venous access was at least possibly related to study drug as determined by the investigator.</description>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (5.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia nos</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="27" subjects_affected="18" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="296" subjects_affected="53" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Migraine nos</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dilatation atrial</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tachycardia nos</sub_title>
                <counts group_id="E1" events="24" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ear haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="34" subjects_affected="24" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" events="88" subjects_affected="27" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain nos</sub_title>
                <counts group_id="E1" events="73" subjects_affected="34" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Diarrhoea nos</sub_title>
                <counts group_id="E1" events="78" subjects_affected="32" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gastroenteritis nos</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Loose stools</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="44" subjects_affected="24" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Umbilical hernia nos</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Vomiting nos</sub_title>
                <counts group_id="E1" events="102" subjects_affected="39" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="22" subjects_affected="12" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Gait abnormal</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="33" subjects_affected="11" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Injection site extravasation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="12" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain nos</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="187" subjects_affected="57" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="17" subjects_affected="11" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ear infection nos</sub_title>
                <counts group_id="E1" events="91" subjects_affected="36" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection nos</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis media nos</sub_title>
                <counts group_id="E1" events="37" subjects_affected="22" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Otitis media serous nos</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pneumonia nos</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection nos</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sinusitis nos</sub_title>
                <counts group_id="E1" events="16" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Skin fungal infection nos</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Tooth caries nos</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection nos</sub_title>
                <counts group_id="E1" events="106" subjects_affected="47" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection viral nos</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Viral infection nos</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abrasion nos</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Limb injury nos</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Post procedural pain</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="81" subjects_affected="39" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="39" subjects_affected="23" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="24" subjects_affected="17" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain in foot</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" events="59" subjects_affected="29" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma nos</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Bronchitis nos</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Bronchospasm nos</sub_title>
                <counts group_id="E1" events="19" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="155" subjects_affected="53" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Dyspnoea nos</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="8" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="100" subjects_affected="38" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="84" subjects_affected="39" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="102" subjects_affected="46" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic nos</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rhinitis nos</sub_title>
                <counts group_id="E1" events="20" subjects_affected="14" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="70" subjects_affected="31" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne nos</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="35" subjects_affected="11" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="27" subjects_affected="11" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="11" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rash nos</sub_title>
                <counts group_id="E1" events="60" subjects_affected="20" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Skin lesion nos</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Urticaria nos</sub_title>
                <counts group_id="E1" events="54" subjects_affected="14" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="32" subjects_affected="9" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Hypotension NOS</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="94"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="94"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Shireâs agreements with investigators vary. All agreements provide Shire the right to embargo communications regarding trial results prior to public release for a period â¤ 180 days from the time submitted to Shire for review. Shire does not prohibit publication but can require the removal of confidential information (excluding trial results) and can request postponement of a single-center publication until after disclosure of the trialâs multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study design was open-label, and the lack of a concurrently followed placebo group limits the strength of the observations, because the progression of the disease is variable and has not been well described.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Arian Pano, Medical Director</name_or_title>
      <organization>Shire Human Genetic Therapies</organization>
      <phone>781-482-0875</phone>
      <email>apano@shire.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

